Hunan Fangsheng Pharmaceutical (603998) Stock Overview
Engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
603998 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Hunan Fangsheng Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.74 |
| 52 Week High | CN¥13.50 |
| 52 Week Low | CN¥9.48 |
| Beta | 0.45 |
| 1 Month Change | -9.29% |
| 3 Month Change | -7.49% |
| 1 Year Change | 9.37% |
| 3 Year Change | -19.00% |
| 5 Year Change | 74.63% |
| Change since IPO | 22.12% |
Recent News & Updates
Recent updates
Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Low P/E No Reason For Excitement
Mar 20
Hunan Fangsheng Pharmaceutical's (SHSE:603998) Earnings Are Weaker Than They Seem
Nov 04The Market Doesn't Like What It Sees From Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Earnings Yet
Jun 06Earnings Troubles May Signal Larger Issues for Hunan Fangsheng Pharmaceutical (SHSE:603998) Shareholders
Apr 30Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) 34% Share Price Surge Not Quite Adding Up
Mar 04Shareholder Returns
| 603998 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.7% | 0.1% | 1.5% |
| 1Y | 9.4% | 14.8% | 33.4% |
Return vs Industry: 603998 underperformed the CN Pharmaceuticals industry which returned 14.8% over the past year.
Return vs Market: 603998 underperformed the CN Market which returned 33.4% over the past year.
Price Volatility
| 603998 volatility | |
|---|---|
| 603998 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 603998 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603998's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,807 | Xiaoli Zhou | www.fangsheng.com.cn |
Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infective drugs. The company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue capsules, Lysine Vitamin B12 granules, Cefuroxime tablets, Jinying capsules, Pudilan anti-inflammatory tablets, Xiaoer Jingxing cough granules, Ezetimibe tablets, Xuanqi bone-strengthening tablets, Qiangli Loquat Paste (honey-refined), and Qiangli Loquat Dew and others.
Hunan Fangsheng Pharmaceutical Co., Ltd. Fundamentals Summary
| 603998 fundamental statistics | |
|---|---|
| Market cap | CN¥4.72b |
| Earnings (TTM) | CN¥295.36m |
| Revenue (TTM) | CN¥1.68b |
Is 603998 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603998 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.68b |
| Cost of Revenue | CN¥511.12m |
| Gross Profit | CN¥1.17b |
| Other Expenses | CN¥876.36m |
| Earnings | CN¥295.36m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 25, 2026
| Earnings per share (EPS) | 0.67 |
| Gross Margin | 69.63% |
| Net Profit Margin | 17.55% |
| Debt/Equity Ratio | 29.0% |
How did 603998 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 18:09 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hunan Fangsheng Pharmaceutical Co., Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wentao Li | Citic Securities Co., Ltd. |
| Wen Dai | Huatai Research |
| Wei Wei | Ping An Securities Co. Ltd. |